相似文献
1
Pseudomonas biofilms, cystic fibrosis, and phage: a silver lining?
mBio. 2012 Apr 3;3(2). doi: 10.1128/mBio.00061-12. Print 2012.
2
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells.
mBio. 2012 Mar 6;3(2):e00029-12. doi: 10.1128/mBio.00029-12. Print 2012.
3
Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.
AAPS J. 2019 Apr 4;21(3):49. doi: 10.1208/s12248-019-0315-0.
4
Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy.
Adv Virus Res. 2014;88:227-78. doi: 10.1016/B978-0-12-800098-4.00005-2.
5
Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model.
Int J Antimicrob Agents. 2015 Aug;46(2):196-200. doi: 10.1016/j.ijantimicag.2015.04.005. Epub 2015 May 27.
6
Pseudomonas aeruginosa bacteriophage PA1Ø requires type IV pili for infection and shows broad bactericidal and biofilm removal activities.
Appl Environ Microbiol. 2012 Sep;78(17):6380-5. doi: 10.1128/AEM.00648-12. Epub 2012 Jun 29.
7
Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.
Appl Environ Microbiol. 2012 Aug;78(16):5646-52. doi: 10.1128/AEM.00757-12. Epub 2012 Jun 1.
8
Bacteriophage Delivery by Nebulization and Efficacy Against Phenotypically Diverse Pseudomonas aeruginosa from Cystic Fibrosis Patients.
J Aerosol Med Pulm Drug Deliv. 2015 Oct;28(5):353-60. doi: 10.1089/jamp.2014.1172. Epub 2015 Feb 25.
9
In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.
Appl Microbiol Biotechnol. 2015 Jul;99(14):6021-33. doi: 10.1007/s00253-015-6492-6. Epub 2015 Mar 12.
10
A genetic approach to the development of new therapeutic phages to fight pseudomonas aeruginosa in wound infections.
Viruses. 2012 Dec 21;5(1):15-53. doi: 10.3390/v5010015.
引用本文的文献
1
Mechanisms and Impact of Biofilms and Targeting of Biofilms Using Bioactive Compounds-A Review.
Medicina (Kaunas). 2021 Aug 18;57(8):839. doi: 10.3390/medicina57080839.
2
Gallium(III)-Salophen as a Dual Inhibitor of Heme Sensing and Iron Acquisition.
ACS Infect Dis. 2020 Aug 14;6(8):2073-2085. doi: 10.1021/acsinfecdis.0c00138. Epub 2020 Jul 6.
3
Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex.
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6200-6. doi: 10.1128/AAC.01198-16. Print 2016 Oct.
4
Characterization of the Newly Isolated Lytic Bacteriophages KTN6 and KT28 and Their Efficacy against Pseudomonas aeruginosa Biofilm.
PLoS One. 2015 May 21;10(5):e0127603. doi: 10.1371/journal.pone.0127603. eCollection 2015.
5
Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings.
Microbiol Insights. 2013 Apr 14;6:29-36. doi: 10.4137/MBI.S10792. eCollection 2013.
6
Clostridium difficile phages: still difficult?
Front Microbiol. 2014 Apr 28;5:184. doi: 10.3389/fmicb.2014.00184. eCollection 2014.
7
A novel Pseudomonas aeruginosa bacteriophage, Ab31, a chimera formed from temperate phage PAJU2 and P. putida lytic phage AF: characteristics and mechanism of bacterial resistance.
PLoS One. 2014 Apr 3;9(4):e93777. doi: 10.1371/journal.pone.0093777. eCollection 2014.
8
Applying insights from biofilm biology to drug development - can a new approach be developed?
Nat Rev Drug Discov. 2013 Oct;12(10):791-808. doi: 10.1038/nrd4000.
9
The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.
PLoS One. 2013 Apr 24;8(4):e60575. doi: 10.1371/journal.pone.0060575. Print 2013.
本文引用的文献
1
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells.
mBio. 2012 Mar 6;3(2):e00029-12. doi: 10.1128/mBio.00029-12. Print 2012.
2
Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention.
PLoS One. 2011 Feb 15;6(2):e16963. doi: 10.1371/journal.pone.0016963.
3
Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2.
Appl Environ Microbiol. 2011 Feb;77(3):756-61. doi: 10.1128/AEM.01848-10. Epub 2010 Dec 10.
4
Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections.
J Infect Dis. 2010 Apr 1;201(7):1096-104. doi: 10.1086/651135.
5
Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.
J Infect Dis. 2010 Jan 15;201(2):264-71. doi: 10.1086/649227.
6
Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system.
Antimicrob Agents Chemother. 2010 Jan;54(1):397-404. doi: 10.1128/AAC.00669-09. Epub 2009 Oct 12.
7
Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa.
J Appl Microbiol. 2010 Feb;108(2):695-702. doi: 10.1111/j.1365-2672.2009.04469.x. Epub 2009 Jul 13.
8
A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.
Clin Otolaryngol. 2009 Aug;34(4):349-57. doi: 10.1111/j.1749-4486.2009.01973.x.
9
Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.
PLoS One. 2009;4(3):e4944. doi: 10.1371/journal.pone.0004944. Epub 2009 Mar 20.
10
The structures of bacteriophages K1E and K1-5 explain processive degradation of polysaccharide capsules and evolution of new host specificities.
J Mol Biol. 2007 Aug 17;371(3):836-49. doi: 10.1016/j.jmb.2007.05.083. Epub 2007 Jun 2.
Zotero 插件